Senior Associate Scientist
- Significant contributions to FDA filings, including MYK-461 (Mavacampten) NDA and MYK-491 (Danicamtiv) IND.- Conducted detailed mechanistic studies on MYK-491 using advanced biophysical techniques (Loaded In-Vitro Motility Assays, optical trap experiments), resolving its mode of action (MOA) compared to other compounds like Omecamtiv Mecarbil.-Led.